A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis

Key Points

• The study aimed to evaluate the effectiveness of guselkumab in achieving GC-free remission in adults with giant cell arteritis.
• Conducted as a phase 2, randomised, placebo-controlled trial.
• Involved adults with new-onset or relapsing giant cell arteritis.
• Compared outcomes between the guselkumab group and placebo group.
• The primary endpoint of GC-free remission was not achieved.
• Findings do not support the effectiveness of guselkumab in treating giant cell arteritis.